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Abstract: Matrix Gla Protein (MGP) is a strong vitamin K-dependent inhibitor of soft tissue
calcification. We assessed the prevalence of functional vitamin K insufficiency, as derived from
plasma desphospho-uncarboxylated MGP (dp-ucMGP), and investigated whether plasma dp-ucMGP
is associated with all-cause and cardiovascular mortality in a large general population-based
cohort. We included 4275 subjects (aged 53 ± 12 years, 46.0% male) participating in the prospective
general population-based Prevention of Renal and Vascular End-Stage Disease (PREVEND) study.
The prevalence of functional vitamin K insufficiency (i.e., dp-ucMGP > 500 pmol/L) was 31% in
the total study population. This prevalence was significantly higher among elderly and subjects
with comorbidities like hypertension, type 2 diabetes, chronic kidney disease, and cardiovascular
disease (~50%). After 10 years of follow-up, 279 subjects had died, with 74 deaths attributable
to cardiovascular causes. We found significant J-shaped associations of plasma dp-ucMGP with
all-cause (linear term: hazard ratio (HR) (95% confidence interval (CI)) = 0.20 (0.12–0.33), p < 0.001;
squared term: 1.14 (1.10–1.17), p < 0.001) and cardiovascular mortality (linear term: 0.12 (0.05–0.27),
p < 0.001; squared term: 1.17 (1.11–1.23), p < 0.001). These associations remained significant after
adjustment for potential confounders. Whether the correction of vitamin K insufficiency improves
health outcomes needs to be addressed in future prospective intervention studies.
Keywords: vitamin K; matrix Gla protein; all-cause mortality; cardiovascular mortality
1. Introduction
Along with aging of the population and the rising prevalence of lifestyle-related diseases like
type 2 diabetes and hypertension, the prevalence of cardiovascular disease has steadily risen all over
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the world [1]. Vascular calcification is common in patients with diabetes, hypertension, and chronic
kidney disease (CKD), and results in a substantially increased risk for cardiovascular disease (CVD)
and mortality [2].
Active matrix Gla protein (MGP) is a strong endogenous inhibitor of soft tissue calcification [3].
Vitamin K is an essential co-factor for the γ-carboxylation of matrix Gla protein (MGP), turning
inactive uncarboxylated MGP into active MGP [4]. Vitamin K occurs as two forms in the diet:
vitamin K1 (phylloquinone) and vitamin K2 (menaquinones). Vitamin K1 is mainly found in green
leafy vegetables and vitamin K2 is mainly found in fermented foods such as cheese and natto [5].
Vitamin K insufficiency results in increased plasma levels of inactive uncarboxylated MGP proteins [6].
Plasma desphospho-uncarboxylated (dp-ucMGP) was found to be particularly sensitive for changes in
vascular vitamin K status [7].
Furthermore, high plasma dp-ucMGP levels, indicative of functional vitamin K insufficiency,
were found to be associated with an increased risk for CVD [8] and mortality [9–12] in patients with
diabetes [8], CKD [9,10], and CVD [11,12]. A recent study demonstrated that high plasma dp-ucMGP
concentrations were associated with an increased risk for mortality in the general population [13].
However, data regarding the prevalence of functional vitamin K insufficiency, and thus its clinical
impact, are incomplete.
Our objectives were to assess the prevalence of vitamin K insufficiency, as derived from dp-ucMGP,
in a large general population-based cohort and to investigate whether vitamin K status is associated
with all-cause and cardiovascular mortality. In addition, we aimed to specify a cut-off value for
dp-ucMGP to identify subjects at risk for all-cause and cardiovascular mortality.
2. Materials and Methods
2.1. Study Design and Population
The PREVEND (Prevention of Renal and Vascular End-Stage Disease) study is a prospective cohort
study designed to investigate the association of microalbuminuria with renal and cardiovascular disease in
the general population. Details of the PREVEND study have been described elsewhere [14,15]. In brief,
from 1997 to 1998, all inhabitants of the city of Groningen, the Netherlands, aged 28–75 years (n = 85,421)
were sent a questionnaire and a vial to collect a first-morning void urine sample. Pregnant women
and subjects with type 1 diabetes were excluded. The urinary albumin concentration was assessed in
40,856 responders. Subjects with a urinary albumin concentration≥10 mg/L (n = 7768) were invited to
participate in the cohort, of whom 6000 were enrolled. In addition, a randomly selected group with a
urinary albumin concentration of <10 mg/L (n = 3394) was invited to participate in the cohort, of whom
2592 were enrolled. These 8592 individuals form the PREVEND cohort. The PREVEND study has been
approved by the medical ethics committee of the University Medical Center Groningen. All participants
provided written informed consent.
The second examination round of the PREVEND study took place from 2001 to 2003, which
included 6894 subjects and was considered the ‘baseline’ for the present study. For the present study,
we included subjects with available dp-ucMGP measurements and available data on the use of vitamin
K antagonists at baseline, leaving 4275 subjects for analyses.
2.2. Data Collection and Measurements
The procedures at each examination in the PREVEND study have been described in detail
previously [15]. In brief, each examination included two visits to an outpatient clinic separated
by 3 weeks. Before the first visit, all participants completed a self-administered questionnaire
regarding demographics, cardiovascular and renal disease history, smoking habits, and medication
use. Information on medication use was combined with information from IADB.nl [16], a database
comprising pharmacy-dispensing data from all community pharmacies in the city of Groningen,
the Netherlands, since 1999. During each examination and during each visit, blood pressure was
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measured on the right arm, every minute for 10 and 8 min, by an automatic Dinamap XL Model
9300 series device (Johnson-Johnson Medical, Tampa, FL, USA). The mean of the last two recordings
from each of the two visits was used. Fasting blood samples were provided and stored at −80 ◦C.
Vitamin K status was assessed by measuring dp-ucMGP in ethylenediaminetetraacetic acid
(EDTA) plasma using a dual-antibody enzyme-linked immunoassay (InaKtif MGP (IDS-iSYS) assay).
Serum creatinine (SCr) was measured using an enzymatic method on a Roche Modular analyzer
(Roche Diagnostics, Mannheim, Germany). Serum cystatin C concentrations were determined by
Gentian Cystatin C Immunoassay (Gentian AS, Moss, Norway) on a Roche Diagnostics Modular
auto-analyzer. Cystatin C was calibrated using the standard supplied by the manufacturer (traceable to
the International Federation of Clinical Chemistry Working Group for Standardization of Serum
Cystatin C). The combined creatinine- and cystatin C-based Chronic Kidney Disease Epidemiology
Collaboration (CKD-EPI) equation was used to obtain the estimated glomerular filtration rate
(eGFR) [17]. Urinary albumin concentration was measured by immunonephelometry (Dade Behring
Diagnostic, Marburg, Germany).
Functional vitamin K insufficiency was defined as a dp-ucMGP concentration >500 pmol/L [7].
Type 2 diabetes was defined as a fasting serum glucose level >7.0 mmol/L, a non-fasting plasma glucose
level >11.1 mmol/L, self-report of a physician diagnosis, or the use of glucose lowering drugs, retrieved
from a central pharmacy registry. Hypertension was defined as systolic blood pressure ≥140 mmHg
or diastolic blood pressure ≥90 mmHg according to the 7th Joint National Committee (JNC 7) [18].
Chronic kidney disease (CKD) was defined as an eGFR <60 mL/min/1.73 m2 and/or a urinary albumin
excretion (UAE) ≥30 mg/24 h.
2.3. Clinical End Points
In the present study, we examined the association of vitamin K status, as derived from dp-ucMGP,
with all-cause and cardiovascular mortality. Data on mortality were obtained from the municipal
register, and the cause of death was obtained by linking the number of the death certificates to the
primary cause of death as coded by a physician from the Central Bureau of Statistics. Cause of death
was coded according to the 10th Revision of the International Classification of Diseases (ICD-10).
Survival time was defined from baseline until the date of last examination that participants attended,
death, relocation to an unknown destination, or 1 January 2011 (end of follow-up).
2.4. Statistical Analyses
Statistical analyses were performed using SPSS version 22.0 for Windows (IBM Corporation,
Chicago, IL, USA), STATA version 13.1 (StataCorp LP, College Station, TX, USA), and R version
3.0.1 (Vienna, Austria) (http://cran.r-project.org/). Results were expressed as means ± standard
deviation (SD) or median (interquartile range (IQR)) for normally and non-normally distributed data,
respectively. Nominal data were presented as the total number of patients (percentage). A two-sided
p < 0.05 was considered to indicate statistical significance.
Baseline characteristics are presented for the total study population and as tertiles of baseline
dp-ucMGP concentrations for illustrative purposes and to identify variables (i.e., potential confounders)
that are associated with plasma dp-ucMGP in cross-sectional analyses. p-values for differences between
tertiles were assessed using ANOVA for normally distributed data, Kruskal-Wallis test for skewed
data, and the χ2 test for nominal data. The χ2 test was used to compare the prevalence of a low vitamin
K status among subjects with and without comorbidities.
We used Cox regression analyses to investigate the prospective association of baseline dp-ucMGP
concentrations with mortality. We applied log2 transformation of dp-ucMGP values so the hazard
ratios derived from Cox regression analyses were expressed as an increase in risk per doubling of
baseline dp-ucMGP values. Cox regression analyses with restricted cubic splines (RCS) with 3 knots
were used to depict the J-shaped association of dp-ucMGP with mortality. Cox regression analyses and
the STATA package mfpigen were used to test for potential interactions between continuous variables.
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Several subjects had missing values for one or more baseline variables (i.e., race, smoking,
education, body mass index (BMI), systolic and diastolic blood pressure, UAE (≤1%),
total cholesterol/high-density lipoprotein (HDL) cholesterol ratio (3.3%), eGFR (5.4%), and high
sensitive C-reactive protein (hs-CRP) (6.0%)). Because excluding subjects with missing values could
result in bias, multiple imputation (fully conditional specification (MCMC)) was used to obtain
five imputed datasets [19,20]. Rubin’s rules were used to obtain pooled estimates of the regression
coefficients and their standard errors across the imputed datasets [21].
Various Cox regression models were built to adjust for possible confounders. The first model
depicts the univariable association of log2 dp-ucMGP with outcomes; model 2 was adjusted for
age and sex; model 3 was additionally adjusted for race, smoking, education, BMI, systolic blood
pressure, cholesterol-HDL ratio, ln hs-CRP, type 2 diabetes, use of antihypertensive drugs, and use
of vitamin K antagonists; model 4 was additionally adjusted for eGFR and ln UAE. As sensitivity
analyses, we additionally adjusted for the presence or absence of a UAE >10 mg/L to test for a potential
sampling effect. In further sensitivity analyses, we repeated the Cox regression analyses in subjects
that did not use vitamin K antagonists at baseline.
Furthermore, we aimed to identify a cut-off value for dp-ucMGP to identify subjects at increased
risk for mortality based on the quantitative measurement of dp-ucMGP. To identify the optimal
cut-off, we used the method described by Liu et al. [22], which is available in the STATA package
cutpt. This method is a nonparametric approach to identify the optimal cut point for a diagnostic test,
which is based on the area under the receiver operating characteristic (ROC) curve, and maximizes the
product of the sensitivity and specificity [22].
3. Results
3.1. Baseline Characteristics
In the present study, we included 4275 subjects (aged 53 ± 12 years, 46.0% male). Out of all
included subjects, 927 (21.7%) had hypertension, 1306 (30.5%) were ≥60 years of age, 84 (2.0%)
had type 2 diabetes, 712 (16.7%) had CKD, and 308 (7.2%) had a history of CVD. Baseline characteristics
of the total study population and according to tertiles of baseline dp-ucMGP concentrations are
presented in Table 1. Median dp-ucMGP concentrations for the total study population (372 (221–552)
pmol/L), for subjects ≥60 years old (506 (336–724) pmol/L), and for subjects with hypertension
(496 (319–693) pmol/L), type 2 diabetes (514 (364–766) pmol/L), CKD (529 (335–773) pmol/L) and
CVD (522 (366–812) pmol/L) are depicted in Figure 1. Dp-ucMGP concentrations were significantly
higher in elderly and subjects with comorbidities such as hypertension, type 2 diabetes, CKD, or CVD,
and increased even further as the number of comorbidities increased (Figure 1). The prevalence
of functional vitamin K insufficiency (i.e., dp-ucMGP > 500 pmol/L) was 31% in the total study
population. This prevalence was significantly higher among the elderly and subjects with comorbidities
like hypertension, type 2 diabetes, chronic kidney disease, and cardiovascular disease (~50%).
Table 1. Baseline characteristics of the study population.
All Subjects (n = 4275)
Tertiles of dp-ucMGP
p-ValueTertile 1 (n = 1425) Tertile 2 (n = 1425) Tertile 3 (n = 1425)
dp-ucMGP (pmol/L) 372 (221–552) <275 275–479 ≥480 -
Demographics
Male gender (n, %) 1966 (46.0) 570 (40.0) 669 (46.9) 727 (51.0) <0.001
Age (years) 53 ± 12 49 ± 11 52 ± 11 59 ± 12 <0.001
Race 0.03
Caucasian (n, %) 4041 (94.5) 1333 (93.5) 1343 (94.2) 1365 (95.8)
Black (n, %) 42 (1.0) 21 (1.5) 13 (0.9) 8 (0.6)
Asian (n, %) 100 (2.3) 36 (2.5) 36 (2.5) 28 (2.0)
Other (n, %) 59 (1.4) 27 (1.9) 21 (1.5) 11 (0.8)
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Table 1. Cont.
All Subjects (n = 4275)
Tertiles of dp-ucMGP
p-ValueTertile 1 (n = 1425) Tertile 2 (n = 1425) Tertile 3 (n = 1425)
Education <0.001
High (n, %) 1431 (33.5) 566 (39.7) 504 (35.4) 361 (25.3)
Middle (n, %) 1015 (23.7) 366 (25.7) 340 (23.9) 309 (21.7)
Low (n, %) 1814 (42.4) 489 (34.3) 576 (40.4) 749 (52.6)
Smoking (n, %) 1206 (28.2) 472 (33.1) 448 (31.4) 286 (20.1) <0.001
Type 2 diabetes (n, %) 84 (2.0) 16 (1.1) 19 (1.3) 49 (3.4) <0.001
History of CVD (n, %) 308 (7.2) 47 (3.3) 86 (6.0) 175 (12.3) <0.001
Clinical measurements
BMI (kg/m2) 26.7 ± 4.3 25.5 ± 3.9 26.4 ± 4.0 28.1 ± 4.5 <0.001
SBP (mmHg) 126 ± 19 121 ± 17 124 ± 18 133 ± 21 <0.001
DBP (mmHg) 73 ± 9 71 ± 9 73 ± 9 75 ± 9 <0.001
Laboratory parameters
Total cholesterol (mmol/L) 5.4 ± 1.1 5.3 ± 1.0 5.5 ± 1.1 5.5 ± 1.1 <0.001
HDL cholesterol (mmol/L) 1.3 ± 0.3 1.3 ± 0.3 1.3 ± 0.3 1.2 ± 0.3 <0.001
Total cholesterol-HDL ratio 4.5 ± 1.3 4.3 ± 1.3 4.5 ± 1.3 4.7 ± 1.2 <0.001
Triglycerides (mmol/L) 1.1 (0.8–1.6) 1.0 (0.8–1.5) 1.1 (0.8–1.5) 1.2 (0.9–1.7) <0.001
hs-CRP (mg/L) 1.4 (0.6–3.1) 1.1 (0.5–2.9) 1.2 (0.6–2.7) 1.8 (0.9–3.6) <0.001
UAE (mg/day) 8.1 (5.9–13.4) 7.6 (5.7–11.4) 7.8 (5.8–12.0) 9.3 (6.3–17.9) <0.001
Serum creatinine (µmol/L) 85 ± 22 81 ± 13 83 ± 14 90 ± 31 <0.001
eGFR (mL/min/1.73 m2) 85 ± 16 90 ± 14 87 ± 14 76 ± 17 <0.001
Medication
Vitamin K antagonists (n, %) 106 (2.5) 5 (0.4) 6 (0.4) 95 (6.7) <0.001
Antihypertensive drugs (n, %) 990 (23.2) 228 (16.0) 252 (17.7) 510 (35.8) <0.001
Lipid-lowering drugs (n, %) 459 (10.7) 98 (6.9) 130 (9.1) 231 (16.2) <0.001
Abbreviations: BMI, body mass index; CVD, cardiovascular diseases; dp-ucMGP, desphospho-uncarboxylated
matrix Gla protein; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; HDL, high-density
lipoprotein; hs-CRP, high sensitive C-reactive protein; SBP, systolic blood pressure; UAE, urinary albumin excretion.
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The J-shaped associations of dp-ucMGP with all-cause and cardiovascular mortality are shown in
Figure 2 and Table 2. Plasma dp-ucMGP was significantly associated with all-cause and cardiovascular
mortality. These associations remained significant after adjustment for potential confounders (Table 2).
The associations of dp-ucMGP with mortality remained materially unchanged after further adjustment
for the presence or absence of a UAE > 10 mg/L. Furthermore, the associations of dp-ucMGP with
mortality remained materially unchanged after exclusion of subjects that used vitamin K antagonists
(Supplementary Table S1).
Finally, we specified a cut-off value for dp-ucMGP to identify subjects at risk for mortality. The optimal
cut-off value was 414 pmol/L for all-cause mortality and 557 pmol/L for cardiovascular mortality.
Table 2. Associations of log2 dp-ucMGP with all-cause and cardiovascular mortality.
All-Cause Mortality (nevents/ntotal = 279/4275) Cardiovascular Mortality (nevents/ntotal = 74/4275)
HR (95% CI) p-Value HR (95% CI) p-Value
Model 1
Linear term 0.20 (0.12–0.33) <0.001 0.12 (0.05–0.27) <0.001
Squared term 1.14 (1.10–1.17) <0.001 1.17 (1.11–1.23) <0.001
Model 2
Linear term 0.27 (0.15–0.47) <0.001 0.14 (0.06–0.38) <0.001
Squared term 1.10 (1.06–1.13) <0.001 1.13 (1.07–1.20) <0.001
Model 3
Linear term 0.36 (0.18–0.72) 0.004 0.15 (0.04–0.48) 0.002
Squared term 1.07 (1.03–1.12) 0.002 1.13 (1.04–1.22) 0.003
Model 4
Linear term 0.33 (0.17–0.66) 0.002 0.17 (0.05–0.58) 0.004
Squared term 1.08 (1.03–1.13) 0.001 1.11 (1.03–1.20) 0.009
Model 1: crude. Model 2: adjusted for age and sex. Model 3: as model 2 + race, smoking, education level,
BMI, SBP, cholesterol-HDL ratio, ln hs-CRP, type 2 diabetes, history of cardiovascular disease, use of antihypertensive
drugs, and use of VKA. Model 4: as model 3 + eGFR and ln UAE. Abbreviations: CI, confidence interval; eGFR, estimated
glomerular filtration rate; HDL, high-density lipoprotein; HR, hazard ratio; hs-CRP, high sensitive C-reactive protein;
SBP, systolic blood pressure; UAE, urinary albumin excretion; VKA, vitamin K antagonists.
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this prevalence was significantly higher (i.e., ~50%), and this prevalence increased even further as
the number of comorbidities increased. Furthermore, we found J-shaped associations of plasma
dp-ucMGP concentrations with all-cause and cardiovascular mortality. These associations remained
significant after adjustment for potential confounders.
Previous studies demonstrated that plasma dp-ucMGP concentrations are significantly higher
in healthy subjects aged 66–80 years compared with subjects aged 25–40 years [7], and that
plasma dp-ucMGP concentrations are markedly increased in patients with cardiovascular and renal
disease [6,9,10,12]. In line with these findings, we found that plasma dp-ucMGP concentrations were
significantly higher among elderly and subjects with comorbidities like hypertension, type 2 diabetes,
CKD, and CVD. Furthermore, we demonstrated that these dp-ucMGP concentrations increased even
further as the number of comorbidities increased.
High plasma dp-ucMGP levels may reflect a low dietary intake of vitamin K, which may contribute
to functional vitamin K insufficiency. Currently, the recommended intake of vitamin K is 90 µg/day for
women and 120 µg/day for men [23]. However, Booth et al. [24] showed that mean vitamin K1 intakes
of 1112 men and 1479 women participating in the Framingham Heart Study were 153 ± 115 µg/day
and 171± 103 µg/day, respectively, implicating that vitamin K intake was inadequate in approximately
40% of the male participants and 20% of the female participants. Cheung et al. [25] showed that
vitamin K intake was inadequate in 72% of participants with CKD from NHANES III. Furthermore,
Fusaro et al. [26] demonstrated in a controlled observational study that vitamin K1 intake was lower
in hemodialysis patients compared with controls. Thus, inadequate intake may, at least partly, explain
the high prevalence of functional vitamin K insufficiency.
Furthermore, current recommendations on intake of vitamin K are exclusively based on vitamin
K1, which is the major dietary form of vitamin K in most Western countries, and its function in
coagulation [27]. However, these recommended intake values do not reflect vitamin K2 and may
be suboptimal for the extra-hepatic functions of vitamin K [27,28]. In addition, several studies have
suggested that vitamin K2, the major dietary form of vitamin K in Japan, may be more effective in
activating extra-hepatic vitamin K-dependent proteins than vitamin K1 [27].
Other important factors that may contribute to functional vitamin K insufficiency are the
composition of the intestinal flora [29] and impaired vitamin K recycling [30]. Kaesler et al. [30]
demonstrated in a preclinical study that the activity of γ-glutamyl carboxylase, the enzyme that
catalyzes the posttranslational γ-carboxylation of vitamin K-dependent proteins such as MGP,
was reduced in CKD. This resulted in increased levels of serum undercarboxylated MGP, indicative
of functional vitamin K insufficiency [30]. Recent findings of McCabe et al. [31] also illustrated
that vitamin K metabolism is altered in CKD, and that this is evident early in the disease course.
Furthermore, Kaesler et al. [30] demonstrated that vitamin K supplementation restored intrarenal
γ-glutamyl carboxylase activity and reduced heart and kidney calcification. Thus, impaired vitamin
K recycling may contribute to functional vitamin K insufficiency in CKD. However, it is not known
whether vitamin K recycling is also affected in subjects with, for example, CVD.
If vitamin K status is insufficient, γ-carboxylation of vitamin K-dependent proteins like osteocalcin
(OC) and MGP will be impaired, resulting in increased levels of inactive undercarboxylated OC and
MGP, which subsequently results in impaired bone metabolism and enhanced vascular calcification [28].
Furthermore, high plasma dp-ucMGP concentrations were found to be associated with an increased
mortality risk in patients with aortic stenosis [11], CVD [12], CKD [9], end-stage renal disease
(ESRD) [10], and renal transplant recipients (RTR) [6]. Recently, Liu et al. found that plasma dp-ucMGP
levels were log-linearly associated with cardiovascular mortality and curvilinearly associated with
all-cause mortality in a general population cohort [13]. In line with these findings, we found that
plasma dp-ucMGP levels were curvilinearly associated with all-cause and cardiovascular mortality in
this large Dutch general population-based cohort.
Furthermore, we aimed to specify a cut-off value for dp-ucMGP to identify subjects at risk for
mortality using a nonparametric approach based on the area under the ROC curve described by
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Liu et al. [22]. We demonstrated that dp-ucMGP levels above 414 pmol/L were associated with an
increased risk for all-cause mortality, and those above 557 pmol/L were associated with an increased
risk for cardiovascular mortality. These findings are in good agreement with the recent findings of
Liu et al. [13], demonstrating that plasma dp-ucMGP levels above 437 pmol/L were associated with
an increased risk for all-cause mortality. Although the cut-off value for vitamin K insufficiency of
500 pmol/L may seem arbitrary, the risk of all-cause and cardiovascular mortality strongly increases
above this threshold, suggesting that this cut-off value is indeed clinically relevant.
Some limitations of the present study need to be addressed. First, given the observational nature
of this study, it is impossible to draw a definite conclusion about the causality of the association of
dp-ucMGP with mortality. However, a recent Mendelian randomization study [13] suggests that the
association of dp-ucMGP with coronary events and non-cancer mortality is causal. This study, however,
might have been underpowered in the Mendelian randomization analysis to detect a significant causal
association of dp-ucMGP with cardiovascular death [13]. Furthermore, data regarding vitamin K
intake or plasma vitamin K concentrations were not available in this study population, and therefore
we could not distinguish between the two forms of vitamin K. However, plasma dp-ucMGP was
found to be a sensitive marker for changes in vascular vitamin K status [7] and is considered to be a
functional marker of bioactivity of both vitamin K1 and K2 [5]. Major strengths of the present study
are the prospective design, the large sample size, and the long-term follow-up.
5. Conclusions
This study provides insights into the prevalence of functional vitamin K insufficiency and its
clinical implications in a large general population-based cohort. We demonstrated that functional
vitamin K insufficiency is common in the general population and occurs even more frequently
among the elderly and subjects with hypertension, type 2 diabetes, CKD, and CVD. Furthermore,
we found that plasma dp-ucMGP was curvilinearly associated with an increased risk for all-cause
and cardiovascular mortality. Importantly, a low vitamin K status is not only a clinically relevant risk
factor for adverse health outcomes, but may also be a modifiable risk factor. Given the availability of
vitamin K supplements, vitamin K insufficiency seems an attractive target for preventive intervention.
Future prospective clinical trials are needed to investigate whether the correction of low vitamin K
status can indeed improve health outcomes.
Supplementary Materials: The following are available online at www.mdpi.com/2072-6643/9/12/1334/s1,
Table S1: Associations of log2 dp-ucMGP with all-cause and cardiovascular mortality after the exclusion of
subjects who used vitamin K antagonists.
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